Skip to main content

Myelitis, Transverse

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
1
Intravenous MethylprednisolonePhase 3
Alder Therapeutics
Alder TherapeuticsSweden - Solna
1 program
1
Intravenous MethylprednisolonePhase 31 trial
Active Trials
NCT02398994Terminated2Est. Mar 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alder TherapeuticsIntravenous Methylprednisolone

Clinical Trials (1)

Total enrollment: 2 patients across 1 trials

NCT02398994Alder TherapeuticsIntravenous Methylprednisolone

A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis

Start: Mar 2015Est. completion: Mar 20162 patients
Phase 3Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.